SB202190 is a selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively (Davies et al.; Jiang et al.) As a pyridinyl imidazole inhibitor, SB202190 directly binds p38 MAP kinases in the ATP binding pocket (Fox et al.)
Improves the self-renewal ability of neural stem cells from NPC1-deficient mice (Yang et al.)
Blocks adiponectin-mediated proliferation of hematopoietic stem cells (DiMascio et al.)
Reduces BMP3-mediated proliferation of C3H10T1/2 mesenchymal stem cells (Stewart et al.)
Induces cardiomyocyte differentiation from human embryonic stem cells (Graichen et al.)
Caractéristiques techniques
Marque
STEMCELL Technologies
Réf. B-LABO
BL-RE-126401
Réf. fabricant
17100102
CAS
152121-30-7
Quantité
10 mg
Formule moléculaire
C<sub>20</sub>H<sub>14</sub>FN<sub>3</sub>O
Pureté
≥98%
Une question, une configuration particulière ? Contactez-nous pour un devis.
